Study of Roxadustat (FG-4592) in Participants With End-Stage Renal Disease Receiving Maintenance Hemodialysis
Public ClinicalTrials.gov record NCT01147666. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Randomized, Open-Label Active-Comparator (Epoetin Alfa) and Single-Blind Placebo-Controlled, Dose-Ranging Safety and Exploratory Efficacy Study of FG-4592 in Subjects With End-Stage Renal Disease Receiving Maintenance Hemodialysis
Study identification
- NCT ID
- NCT01147666
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Kyntra Bio
- Industry
- Enrollment
- 161 participants
Conditions and interventions
Conditions
Interventions
- Epoetin Alfa Drug
- Placebo Other
- Roxadustat Drug
Drug · Other
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 16, 2010
- Primary completion
- Oct 14, 2012
- Completion
- Oct 14, 2012
- Last update posted
- Jan 10, 2022
2010 – 2012
United States locations
- U.S. sites
- 25
- U.S. states
- 14
- U.S. cities
- 25
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Tempe | Arizona | — | — |
| Not listed | Pine Bluff | Arkansas | — | — |
| Not listed | Azusa | California | — | — |
| Not listed | Los Angeles | California | — | — |
| Not listed | Northridge | California | — | — |
| Not listed | Ontario | California | — | — |
| Not listed | Paramount | California | — | — |
| Not listed | Yuba City | California | — | — |
| Not listed | Miami | Florida | — | — |
| Not listed | Pembroke Pines | Florida | — | — |
| Not listed | Honolulu | Hawaii | — | — |
| Not listed | Louisville | Kentucky | — | — |
| Not listed | Detroit | Michigan | — | — |
| Not listed | Kansas City | Missouri | — | — |
| Not listed | Paterson | New Jersey | — | — |
| Not listed | New York | New York | — | — |
| Not listed | Rosedale | New York | — | — |
| Not listed | Williamsville | New York | — | — |
| Not listed | Toledo | Ohio | — | — |
| Not listed | Orangeburg | South Carolina | — | — |
| Not listed | Arlington | Texas | — | — |
| Not listed | Fort Worth | Texas | — | — |
| Not listed | Houston | Texas | — | — |
| Not listed | San Antonio | Texas | — | — |
| Not listed | Fairfax | Virginia | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01147666, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 10, 2022 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01147666 live on ClinicalTrials.gov.